|Number of Estimates|
Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
Market Cap: 375 Million
Primary Exchange: NASDAQ Capital Market
Shares Outstanding: 100 Million
Float: 92.6 Million
Dividend: 0.0 (0.0%)
Short Interest (Jan 12, 2018): 9.25 Million
Longest drawdown: 1090 trading days
From: 2015-06-17 To: 2019-10-11
Agenus to Host Annual Meeting of Stockholders
via: PR Newswire at 2019-06-13 11:48:00:000
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stoc… read more...
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|